Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial (Q58082830)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 February 2019

Language	Label	Description	Also known as
English	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial	scientific article published on 01 February 2019

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

author name string

Lillian L Siu

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Caroline Even

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Ricard Mesía

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Eva Remenar

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Amaury Daste

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Jean-Pierre Delord

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Jürgen Krauss

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Nabil F Saba

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Lisle Nabell

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Neal E Ready

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Irene Braña

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Nuria Kotecki

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Dan P Zandberg

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Jill Gilbert

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Marcelo Bonomi

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Anthony Jarkowski

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Giovanni Melillo

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Jon M Armstrong

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Sophie Wildsmith

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Jérôme Fayette

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

language of work or name

0 references

publication date

1 February 2019

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

195-203

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

End points for new agents in induction chemotherapy for locally advanced head and neck cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal treatment for recurrent/metastatic head and neck cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tremelimumab: a review of development to date in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/30383184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMAONCOL.2018.4628

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30383184%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58082830&oldid=2246564765"